Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Contradictory immune responses explain different therapeutic effects in rheumatoid arthritis

07.11.2005


Using a humanized mouse model that mimics the effects of human rheuma-toid arthritis (RA), researchers have discovered that protein growth factors called cytokines in the immune system have both pro- and anti-inflammatory responses to RA that help explain why some patients respond to current therapy and others don’t. By pinpointing the unique immune mecha-nisms involved in different forms of RA, the scientists hope to guide physicians toward more pre-cise individualized diagnosis of RA patients and more effective therapies that target specific forms of the disease.



The findings were published online on October 20 and are reported in the November issue of the Journal of Clinical Investigation. The research was conducted at the Lowance Center for Human Immunology at Emory University School of Medicine, and was led by rheumatologists Cornelia Weyand, MD, PhD, and Jorg Goronzy, MD, PhD. The study’s first author was Thor-sten M. Seyler.

Rheumatoid arthritis (RA) is a chronic and crippling inflammatory joint, bone and cartilage disease affecting more than 2.1 million Americans. An autoimmune disease, RA is characterized by an abnormal immune response in which the immune system attacks healthy tissue, causing in-flammation of the lining of the joints, called the synovium.


For the last 20 years researchers, including those at Emory, have worked to identify path-ways and molecules that play a role in RA, resulting in new therapies that target inflammatory growth factors and a marked improvement in treatment success. However, even though not all RA patients respond well to these therapies, they are applied universally, without accounting for differ-ences in disease.

"We need to become much more sophisticated as rheumatologists in understanding that RA is not all the same disease and that when we treat it we will see very diverse results," said Dr. Weyand. "Rheumatologists need to develop diagnostic tools to capture differences in patients that have meaning for the course of disease and for our therapeutic actions."

Drs. Weyand and Goronzy have helped delineate three different subtypes of RA disease over the past ten years. In diffuse RA, T and B lymphocytes seem to infiltrate tissue randomly, re-sulting in autoimmune inflammation. In aggregate synovitis, T and B cells meet each other in ag-gregates and inflame the joints. In germinal center synovitis, T cells, B cells, and other supporting cell populations go into the joints and acquire a highly complex and organized micro-architecture that resembles conditions in an inflamed lymph node.

Many therapies currently used to treat RA patients are based on new knowledge about in-flammatory cytokines ÐÐ growth factor-like proteins that stimulate the autoimmune process. Scien-tists have hypothesized that rheumatoid lesions produce excessive amounts of such growth factors, promoting lymphocyte proliferation and keeping alive the immune cells that drive inflammation and perpetuate the autoimmune disease state.

The Emory scientists set out to explore differences in immune responses by using their mouse model to study related types of cytokine protein known for helping B lympocytes survive and differentiate. Two of these proteins, known as APRIL (A proliferation inducing ligand) and BlyS (B-lymphcyte stimulator), are the targets of new experimental drugs currently in early phase clinical trials.

The researchers implanted human tissue from RA patients who had the three different types of disease into mice engineered to lack a natural immune response. They treated the mice with a soluble receptor called TACI that "plucks" the growth factors APRIL and BlyS and "mops" them away from the affected tissue.

The researchers found that in the mice carrying tissue from patients with germinal center synovitis, the inflammatory lymph-node like structures completely collapsed, effectively halting the inflammatory process. However, in the other two types of disease just the opposite happened, and the growth factors and inflammation actually increased.

"This was a very surprising result," said Dr. Weyand. "We found that these two factors do more than just support the growth and differentiation of B cells. They also can bind to T lympho-cytes. In the tissues that had worsening of disease, we found T cells binding APRIL and BLyS, telling us that these T cells had actually been suppressing the disease."

The conclusion? The factors APRIL and BlyS have multiple and complex effects in rheu-matoid arthritis. In some types of disease they are critical in keeping the inflammatory structures working and functioning, while in other types of disease they seem to do just the opposite.

"Physicians and patients already have been aware that some people respond to therapy while others do not," Dr. Weyand says. "Our research helps us explain why. These molecules have both pro- and anti-inflammatory activity, and the trial-and-error method of treatment may not be best for the patient. The goal of current RA treatment is to suppress the immune system, but we need to recognize that nature has developed anti-inflammatory pathways that we may be able to utilize."

Dr. Weyand and Goronzy say the goal of their research is to learn more about physiological ways of downregulating inflammation and strengthening them instead of destroying the entire im-mune response. They also want to develop molecular screening methods to distinguish RA pa-tients, ideally using a simple blood teest.

"We want to move away from making global, unsophisticated diagnoses and design ther-apy plans for patients that match their particular needs," says Dr. Weyand. "We can gain clues from nature about how it inhibits inflammation that will allow us to develop a whole new way of managing the auto-immune response."

Other study authors included Yong W. Park, Seisuke Takemura, from Emory’s Lowance Center for Human Immunology; Richard J. Bram, Department of Pediatrics and Adolescent Medi-cine, the Mayo Clinic; and Paul J. Kurtin, Department of Pathology, the Mayo Clinic.

Holly Korschun | EurekAlert!
Further information:
http://www.emory.edu

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>